Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
Alex K. Bryant, Jacqueline R. Lewy, R. Daniel Bressler, Zoey Chopra, Derek J Gyori, Brian Bazzell, Julie Moeller, Sofia I Jacobson, A. Mark Fendrick, Eve A. Kerr, Nithya Ramnath, Michael D. Green, Timothy P. Hofer, Parth Vaishnav, Garth W. Strohbehn
Topics & Concepts
PembrolizumabDosingPublic healthEnvironmental healthInterval (graph theory)MedicineExploratory analysisConfidence intervalComputer scienceInternal medicineData scienceMathematicsCancerNursingCombinatoricsImmunotherapyCancer Immunotherapy and BiomarkersClimate Change and Health ImpactsPsoriasis: Treatment and Pathogenesis